-
Mashup Score: 15
Tags: 2023, AHA, Cardiology, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 37
Tags: 2023, AHA, Cardiology, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Coronary inflammation using fat attenuation index (FAI) on CCTA may be an independent risk of cardiac events. Dr. Antoniades and I discuss the results of the OFRAN study on using AI technology to improve risk stratification. Link here: https://t.co/7ZGGUnAyJB #AHA23 https://t.co/QDl7iWbo2j
-
-
Mashup Score: 52Dr. Daniel Judge and Dr. C. Michael Gibson: Acoramidis from bench to bedside – Clinical Trial Results - 1 year(s) ago
Tags: 2023, AHA, Cardiology, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
#Acoramidis for #amyloidosis: From bench to bedside with Dr. Daniel Judge https://t.co/0n5czm1VW2 #AHA23 https://t.co/6nr0tpl2uz
-
-
Mashup Score: 72
Tags: 2023, AHA, Cardiology, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Is reducing Lp(a) to undetectable levels feasible? Lepodisiran phase 1 trial shows promising results. Watch my interview with Dr. Steven Nissen on phase 1 trial for lepodisiran effect in reducing Lp(a) https://t.co/bLFWpVgaB7 #AHA23. https://t.co/5V6ae1Y2AB
-
-
Mashup Score: 107
Tags: 2023, AHA, Cardiology, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Changing a single DNA base-pair letter of the PCSK9 gene by VERVE-1 infusion significantly reduces LDL in humans. VERVE-1 moves forward to evaluate clinical effect. Watch my interview with Dr. Bellinger and Dr. Kathiresan. https://t.co/WFx4uhnaVw #AHA23 https://t.co/Vim9dQGeT6
-
-
Mashup Score: 53
Tags: 2023, AHA, Cardiology, slides, Trial, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
No difference in edoxaban efficacy for patients with long atrial high rate episodes > 24h vs. short episodes < 24h. Dr. Becher and I discuss results of subanalysis from NOAH-AFNET 6 trial. Link here: https://t.co/2F7cjV1DET #AHA23 https://t.co/5UeiBk0TUP
-
-
Mashup Score: 68
Tags: 2023, AHA, Cardiology, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Abelacimab significantly reduces bleeding compared to rivaroxaban in AF patients at moderate/high risk of stroke. Watch my interview with Dr. Christian Ruff on results from AZALEA-TIMI-71 https://t.co/m72hLm2YwJ #AHA23 https://t.co/SykezrmZbL
-
-
Mashup Score: 27
Tags: 2023, AHA, Cardiology, slides, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
KARDIA-1 trial shows that RNA interference with zilebesiran in HTN patients is safe, significantly cuts mean ambulatory SBP vs placebo. Dr. Bakris and I discuss results here. Video Link: https://t.co/NIjDxAwytS #AHA23 https://t.co/VUxdVDk3xF
-
-
Mashup Score: 36
Tags: 2023, AHA, Cardiology, slides, video
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Excluding aspirin from antithrombotic regimen for LVAD HeartMate 3 does not increase thrombotic risk, ARIES-HM3 trial shows. Watch my interview with Dr. Mehra here. URL link: https://t.co/6eikF6fpzH #AHA23 https://t.co/38XefEkLA3
-
-
Mashup Score: 76
Article Navigation Dr. Jeffrey Carson and Dr. Serge Korjian Discuss: Restrictive versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial
Source: clinicaltrialresults.orgCategories: General Medicine News, Expert PicksTweet-
Anti-anginal meds vs. anti-anginal procedure? The placebo-controlled ORBITA-2 trial demonstrates benefit with PCI in improving anginal symptoms in stable CAD. Watch my interview with Dr. Rajkumar and Dr. Al-Lamee on ORBITA-2. Link here: https://t.co/DMxekVsACG #AHA23 https://t.co/9pExWfdLEc
-
Dr. Richard Wright & I discuss the Genetic / Mendalian randomization (natures randomized trial) data that supports the efficacy of #Acoramadis in amyloidosis and the potential for amyloid regression with therapy. Link here: https://t.co/v3XJnvpLZc #AHA23 https://t.co/YOazSHrY8b